Systemic Sclerosis (Scleroderma) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis – Drugs in Development, 2021, provides an overview of the Systemic Sclerosis (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 19, 11, 2, 40 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Immunology).

– The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Systemic Sclerosis (Immunology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Systemic Sclerosis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl

Acceleron Pharma Inc

Accuitis Pharmaceuticals Inc

AKL Research and Development Ltd

Allysta Pharmaceuticals Inc

Amgen Inc

AnaMar AB

arGentis Pharmaceuticals LLC

Aryogen Pharmed Co

AstraZeneca Plc

Atlantic Healthcare Plc

Aurora Research Institute LLC

Avotres Inc

Biogen Inc

Biomendics LLC

Blade Therapeutics Inc

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Cantargia AB

Castle Creek Biosciences Inc

Celdara Medical LLC

Centessa Pharmaceuticals Ltd

Certa Therapeutics Pty Ltd

ChemomAb Ltd

Chugai Pharmaceutical Co Ltd

Civi Biopharma Inc

CohBar Inc

Corbus Pharmaceuticals Inc

CSL Ltd

Cumberland Pharmaceuticals Inc

Cureveda LLC

D&D Pharmatech Co Ltd

Emerald Health Sciences Inc

Ergon Pharmaceuticals LLC

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals Co Ltd

Fresenius Kabi SwissBioSim GmbH

Galapagos NV

Galecto Biotech ApS

GenKyoTex SA

Genmab AS

Gilead Sciences Inc

GlaxoSmithKline Plc

GNI Group Ltd

H. Lundbeck AS

Horizon Therapeutics Plc

iBio Inc

Ichnos Sciences Inc

Iltoo Pharma

ImmuneMed Inc

Johnson & Johnson

Kadmon Corp LLC

Leadiant Biosciences Inc

Link Genomics Inc

Luminary Therapeutics Inc

MDI Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Ono Pharmaceutical Co Ltd

Opsidio LLC

Panorama Research Inc

Patagonia Pharmaceuticals LLC

PDX Pharmaceuticals LLC

Peptinov SAS

Pfizer Inc

Processa Pharmaceuticals Inc

RadBio

Regeneron Pharmaceuticals Inc

Resolys Bio Inc

Ribomic Inc

Riptide Bioscience Inc

Samumed LLC

Seagen Inc

Signablok Inc

Takeda Pharmaceutical Co Ltd

Talaris Therapeutics Inc

Timber Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Tvardi Therapeutics Inc

Unity Biotechnology Inc

Vicore Pharma AB

Table of Contents

Table of Contents

Introduction

Systemic Sclerosis (Scleroderma) - Overview

Systemic Sclerosis (Scleroderma) - Therapeutics Development

Systemic Sclerosis (Scleroderma) - Therapeutics Assessment

Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development

Systemic Sclerosis (Scleroderma) - Drug Profiles

Systemic Sclerosis (Scleroderma) - Dormant Projects

Systemic Sclerosis (Scleroderma) - Discontinued Products

Systemic Sclerosis (Scleroderma) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Companies, 2021 (Contd..4)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Target, 2021 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Acceleron Pharma Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Accuitis Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by AKL Research and Development Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Allysta Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Amgen Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by AnaMar AB, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by arGentis Pharmaceuticals LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Aryogen Pharmed Co, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by AstraZeneca Plc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Atlantic Healthcare Plc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Aurora Research Institute LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Avotres Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Biogen Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Biomendics LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Blade Therapeutics Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by BriaCell Therapeutics Corp, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Bristol-Myers Squibb Co, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Cantargia AB, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Castle Creek Biosciences Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Celdara Medical LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Centessa Pharmaceuticals Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Certa Therapeutics Pty Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by ChemomAb Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Chugai Pharmaceutical Co Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Civi Biopharma Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by CohBar Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Corbus Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by CSL Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Cumberland Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Cureveda LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by D&D Pharmatech Co Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Emerald Health Sciences Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Ergon Pharmaceuticals LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Foresee Pharmaceuticals Co Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Fresenius Kabi SwissBioSim GmbH, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Galapagos NV, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Galecto Biotech ApS, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by GenKyoTex SA, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Genmab AS, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Gilead Sciences Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by GlaxoSmithKline Plc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by GNI Group Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by H. Lundbeck AS, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Horizon Therapeutics Plc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by iBio Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Ichnos Sciences Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Iltoo Pharma, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by ImmuneMed Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Johnson & Johnson, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Kadmon Corp LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Leadiant Biosciences Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Link Genomics Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Luminary Therapeutics Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by MDI Therapeutics Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Mitsubishi Tanabe Pharma Corp, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Ono Pharmaceutical Co Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Opsidio LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Panorama Research Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Patagonia Pharmaceuticals LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by PDX Pharmaceuticals LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Peptinov SAS, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Pfizer Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Processa Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by RadBio, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Resolys Bio Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Ribomic Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Riptide Bioscience Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Samumed LLC, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Seagen Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Signablok Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Talaris Therapeutics Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Timber Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by TRACON Pharmaceuticals Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Tvardi Therapeutics Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Unity Biotechnology Inc, 2021

Systemic Sclerosis (Scleroderma) – Pipeline by Vicore Pharma AB, 2021

Systemic Sclerosis (Scleroderma) – Dormant Projects, 2021

Systemic Sclerosis (Scleroderma) – Dormant Projects, 2021 (Contd..1)

Systemic Sclerosis (Scleroderma) – Dormant Projects, 2021 (Contd..2)

Systemic Sclerosis (Scleroderma) – Discontinued Products, 2021

Systemic Sclerosis (Scleroderma) – Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports